ADMA BIOLOGICS, INC. Segment Expenditure Addition To Long Lived Assets
ADMA BIOLOGICS, INC. (ADMA) reported Segment Expenditure Addition To Long Lived Assets of $5.47 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Notes › Segment Reporting
us-gaap:SegmentExpenditureAdditionToLongLivedAssets · last filed 2024-11-07
- ADMA BIOLOGICS, INC. segment expenditure addition to long lived assets for the quarter ending 2024-09-30 was $1.06M, a 39.50% increase year-over-year.
- ADMA BIOLOGICS, INC. segment expenditure addition to long lived assets for the quarter ending 2024-06-30 was $2.07M, a 136.93% increase year-over-year.
- ADMA BIOLOGICS, INC. segment expenditure addition to long lived assets for the quarter ending 2024-03-31 was $2.35M, a 20.67% increase year-over-year.
- ADMA BIOLOGICS, INC. segment expenditure addition to long lived assets for the quarter ending 2023-12-31 was $1.20M, a 68.07% decline year-over-year.
- ADMA BIOLOGICS, INC. segment expenditure addition to long lived assets for fiscal 2023 was $4.77M, a 65.70% decline from fiscal 2022.
- ADMA BIOLOGICS, INC. segment expenditure addition to long lived assets for fiscal 2022 was $13.91M, a 2.96% increase from fiscal 2021.
- ADMA BIOLOGICS, INC. segment expenditure addition to long lived assets for fiscal 2021 was $13.51M.
| Period end | Segment Expenditure Addition To Long Lived Assets 3 month | Segment Expenditure Addition To Long Lived Assets 6 month | Segment Expenditure Addition To Long Lived Assets 6 month as first filed | Segment Expenditure Addition To Long Lived Assets 9 month | Segment Expenditure Addition To Long Lived Assets 9 month as first filed | Segment Expenditure Addition To Long Lived Assets 12 month |
|---|---|---|---|---|---|---|
| 2024-09-30 | $1.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $3.12M derived: sum of 2 quarters · filed 2024-11-07 | $5.47M 10-Q · filed 2024-11-07 | $6.67M derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2024-06-30 | $2.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $4.41M 10-Q · filed 2024-08-08 | $5.61M derived: sum of 3 quarters · filed 2024-08-08 | $6.37M derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2024-03-31 | $2.35M 10-Q · filed 2024-05-09 | $3.54M derived: sum of 2 quarters · filed 2024-05-09 | $4.30M derived: sum of 3 quarters · filed 2024-11-07 | $5.17M derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2023-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $1.95M derived: sum of 2 quarters · filed 2024-11-07 | $2.83M derived: sum of 3 quarters · filed 2024-11-07 | $4.77M 10-K · filed 2024-02-28 | ||
| 2023-09-30 | $757.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.63M derived: sum of 2 quarters · filed 2024-11-07 | $3.57M 10-Q · filed 2024-11-07 | $3.57M 10-Q · filed 2023-11-08 | $7.32M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $872.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $2.82M 10-Q · filed 2024-08-08 | $2.82M 10-Q · filed 2023-08-09 | $6.57M derived: sum of 3 quarters · filed 2024-08-08 | $9.95M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $1.95M 10-Q · filed 2024-05-09 | $5.69M derived: sum of 2 quarters · filed 2024-05-09 | $9.07M derived: sum of 3 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $3.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $7.13M derived: sum of 2 quarters · filed 2024-02-28 | $13.91M 10-K · filed 2024-02-28 | |||
| 2022-09-30 | $3.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $10.16M 10-Q · filed 2023-11-08 | ||||
| 2022-06-30 | $6.78M 10-Q · filed 2023-08-09 | |||||
| 2021-12-31 | $13.51M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |